

MEDIA RELEASE

SHAH ALAM, 2 DECEMBER 2021

PHARMANIAGA DELIVERS SINOVAC COVID-19 VACCINE ON THE 1ST OF AUGUST 2021, AHEAD OF TIME AS REQUESTED BY THE GOVERNMENT TO ACCELERATE NATIONAL COVID-19 IMMUNISATION PROGRAMME

Pharmaniaga Berhad (Pharmaniaga) would like to respond to some media reports yesterday that have wrongly quoted the Public Accounts Committee (PAC) report that the Government paid vaccine manufacturer Sinovac Biotech Ltd (Sinovac) a premium for certain doses to make up for alleged delays caused by Pharmaniaga's fill and finish process.

We wish to clarify that Pharmaniaga completed its 12 million doses contractual delivery schedule, 4 months ahead of time, and the Malaysian Government paid a slightly higher price for additional orders of finished Sinovac COVID-19 vaccine from China to accelerate the completion of the National COVID-19 Immunisation Programme (PICK).

It is pertinent to note that contractually, Pharmaniaga's obligation was to deliver 12 million doses of Sinovac fill and finish vaccine from its high-tech, EU certified plant, Pharmaniaga LifeScience Sdn Bhd (PLS). In reality, the Government requested PLS to deliver both finished as well as filled and finished Sinovac COVID-19 vaccines to accelerate vaccinations in the country through PICK.

This was also best explained by then Minister of Science, Technology and Innovation YB Khairy Jamaluddin in the same PAC report. "We had to pay a premium, (a decision) which the Cabinet agreed to. That's because we wanted to accelerate things. Otherwise, we would have to wait until October," said YB Khairy during a meeting with the PAC on 27 July.

It was further stated in the said report that lack of clarity in the weekly schedule delivery from other suppliers affected appointment scheduling. There were delivery delays of promised vaccines from other COVID-19 vaccine manufacturers.

With the increased cases of COVID-19 infections in May, supporting the Government's initiative in reaching herd immunity faster than planned was achievable as Pharmaniaga had access to the finished vaccines readily available from Sinovac in China.

FOR IMMEDIATE RELEASE

MEDIA RELEASE

Again, the Group wishes to reiterate that Pharmaniaga has been very consistent with its commitment to the Government in meeting the delivery of Sinovac fill and finish vaccine by PLS and went beyond to support the Ministry of Health, which in turn, able to perform exceptionally well in managing the pandemic.

At Pharmaniaga, we maintain the highest standards of corporate governance and transparency in all our business dealings, and we will not hesitate to take legal action against anyone who continues to malign the reputation and integrity of the Company.

Pharmaniaga is the leading pharmaceutical Company of Boustead Holdings Berhad group of companies, and together with Lembaga Tabung Angkatan Tentera, are the major shareholders of the Company.

-END-

About Pharmaniaga Berhad

Pharmaniaga is the leading pharmaceutical company of Boustead Holdings Berhad Group of Companies, which together with the Armed Forces Fund Board, are the major shareholders of the Company. Listed on the Main Board of Bursa Malaysia, Pharmaniaga's core businesses are generic pharmaceuticals manufacturing; research and development; marketing and sales; warehousing and distribution of pharmaceutical and medical products; supply, trading and installation of medical and hospital equipment as well as community pharmacy.

With a vision to be the premier Malaysian pharmaceutical company, Pharmaniaga is guided by its philosophy of 'Do It Right Always' and is empowered by its motto of Passion for Patients. Strengthened by nine manufacturing plants, nationwide logistics and distribution in Malaysia and Indonesia as well as products registered in 15 countries, Pharmaniaga Group is positioned to be a regional player in the international pharmaceutical arena.

Forward-looking statement

This release may contain certain forward-looking statements with respect to the financial conditions, results of operations and business of the Group and certain plans and objectives of Pharmaniaga Berhad with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Issued for Pharmaniaga Group by Corporate Communications Department, Pharmaniaga Berhad. For media enquiries, please contact Dato' Zuhri Iskandar Kamarzaman, Corporate Services Deputy Director of Pharmaniaga Berhad at 03-3342 999 ext 434 or by email zuhri@pharmaniaga.com.